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Summary 
Background: Association between endocan and non-
traditional anthropometric indices, as distinct cardio -
vascular disease risk factors, has not been examined in
previous studies. Endocan is a novel inflammation
biomarker with its higher levels involved in cardiometabolic
diseases development. Taking into consideration that
obesity is an independent risk factor for many cardio -
metabolic diseases, we aimed to explore the relationship
between endocan levels and novel anthropometric indices
i.e., body adiposity index (BAI), cardiometabolic index
(CMI), a body shape index, body roundness index, conicity
index, lipid accumulation product index and visceral
adiposity index and traditional ones i.e., waist circum -
ference, hip circumference, body mass index, waist-to-
height ratio and waist-to-hip ratio in adult population.
Methods: A total of 177 participants were included.
Anthropometric indices and biochemical parametres were
measured. 
Results: Univariate regression analysis demonstrated posi-
tive correlations of endocan and almost all anthropometric
data. To explore independent associations of endocan and
anthropometric parameters, the Model which fulfilled crite-
ria for ordinal regression testing was created. Adjusted
Kratak sadr`aj
Uvod: Povezanost endokana sa netradicionalnim antropo -
metrijskim parametrima, kao razli~itim faktorima rizika za
kardiovaskularne bolesti, nije ispitivana u prethodnim stu -
dijama. Endokan je novi biomarker inflamacije, ~ije su ve}e
vrednosti zabele`ene kod kardiometaboli~kih pore me}aja.
Znaju}i da je gojaznost nezavisan faktor rizika za mnoga
kardiometaboli~ka oboljenja, cilj je bio da se ispita poveza -
nost endokana i novih antropometrijskih pokazatelja tj.
indeks telesne gojaznosti (BAI), kardiometaboli~ki indeks
(CMI), indeks oblika tela, indeks zaokru`enosti tela, indeks
koniciteta, indeks produkata lipidne akumulacije i indeks
visceralne gojaznosti i onih tradicionalnih tj. obim struka,
obim kukova, indeks telesne mase, odnos obim struka/
telesna visina, odnos obim struka/obim kukova u popu -
 laciji odraslih.
Metode: Ukupno 177 ispitanika je u~estvovalo u istra ̀ i -
vanju. Mereni su antropometrijski i biohemijski parametri.
Rezultati: Univarijantna regresiona analiza je pokazala po -
zitivnu korelaciju endokana i skoro svih ispitivanih antro po -
metrijskih parametara. U cilju daljeg ispitivanja po stojanja
nezavisnih korelacija endokana i antropometrijskih para -
metara, kreiran je Model koji je zadovoljio kriterijume za
ordinalnu regresiju. Prilago|eni Odds-ovi za BAI u Modelu
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Introduction 
Endocan is an intriguing proteoglycan tightly
connected with endothelial dysfunction and con -
comitant inflammation (1). Recent studies have
shown higher level of this inflammation marker in
many cardiometabolic diseases, such as type 2
diabetes (2), chronic kidney disease (3), fatty liver
disease (4), hypertension (5).
On the other hand, obesity is an established risk
factor for such cardiometabolic diseases (6, 7). The
increased inflammation markers in adipocites and
disbalance in free radicals production and antioxidant
defence, increased flux of free fatty acids and
dysfunction of hepatocytes, are some of the potential
mechanisms linking obesity and cardiovascular
disease (CVD). In addition to this, impaired insulin
signaling pathways, diminished nitric oxide pro duction
with associated vasoconstriction and endothelial
dysfunction are also contributing mecha nisms to such
pathophysiology (7–10).
However, there are discordant results about
relationship between serum endocan level and
obesity. Namely, some studies reported lower
endocan levels in the obese state (11), as well as an
inverse association between circulating level of
endocan and the most commonly used obesity
indices, such as body mass index (BMI) (12–14) and
waist circumference (WC) (15) in different population
groups. Contrary to this, the others showed the
positive association between circulating endocan level
and mentioned obesity indices, BMI (16–18) and WC
(18). 
Knowing that several recent studies revealed
discrepant results considering this relationship with
traditional anthropometric parameters, we aimed to
obtain deeper understanding into the potential link
between obesity and serum endocan level. Importantly,
no studies have examined the association between
endocan and non-traditional anthropometric indices so
far. In line with this, numerous researches suggest that
novel non-traditional anthropometric parameters can
be better indicators of higher cardio metabolic risk, than
traditional commonly used ones (19–25). 
Therefore, this study aimed to explore the
relationship between endocan levels and new anthro -
pometric indices i.e., body adiposity index (BAI),
cardiometabolic index (CMI), a body shape index
(ABSI), body roundness index (BRI), conicity index
(CI), lipid accumulation product index (LAP) and
visceral adiposity index (VAI) and traditional ones
i.e., BMI, WC, hip circumference (HC), waist-to-




A total of 177 individuals (70.6% women) partici -
pated in this cross-sectional study. The research was
conducted between May and July 2017 in the Primary
Health Care Center in Podgorica, Monte negro. The
Institutional Ethics Committee approved the research
protocol. Participants were enrolled in a consecutive
manner and each of them signed an informed consent
of willingness to be included in the study. 
The eligibility to enter the study were: subjects
older than 18 years, free of diabetes, CVD, chronic
kidney disease, carcinomas, autoimmune and
inflammatory diseases, as well as without endocrine
disorders (e.g., hypo- and hyperthyroidism, Cushing
disease). Another criterion for the persons to be
included in this study was that they were not under
any weight loss programme and that their body
weight did not vary in the previous 3 months.
Exclusion criteria were: alcohol consumption,
acute inflammation high sensitivity C-reactive protein
(hsCRP) >10 mg/L, pregnancy, lactation, as well as
biochemical confirmation of diabetes (i.e., fasting
glucose 7.0 mmol/L, or glucose level  11.1
mmol/L, 2 hours after an oral glucose tolerance test,
or glycated hemoglobin level  6.5% on two different
determinations), anti-inflammatory and antidiabetic
drugs use.
Traditional anthropometric parameters were
taken (weight, height, WC, HC), and BMI, WHtR and
WHR were calculated, as described elsewhere (19).
odds for BAI given in the Model (OR=1.120, 95% CI
1.036–1.212, P=0.004), demonstrated that a rise in BAI
by 1 unit increased the probability of higher endocan con-
centration by 12%. As well, a rise in CMI for 1 unit,
increased the probability for higher endocan levels for 2.6
times (OR=2.599, 95% CI 1.006–6.712, P=0.049). A
total of 20.1% of variation in endocan levels could be
explained by this Model.
Conclusions: Non-traditional obesity indices, BAI and CMI
independently correlated with higher serum endocan levels
in adult population.
Keywords: cardiometabolic risk, endocan, inflammation,
obesity
(OR=1,120, 95% CI 1,036–1,212, P=0,004), su pokazali
da je porast BAI za 1 jedinicu pove}ao verovatno}u za
porast koncentracije endokana za 12%. Tako|e, porast
CMI za 1 jedinicu, pove}ao je verovatno}u za ve}e vred -
nosti endokana za 2,6 puta (OR=2,599, 95% CI 1,006–
6,712, P=0,049). Ukupno 20,1% varijabiliteta u vrednos-
tima koncentracije endokana mo`e biti obja{njeno ovim
Modelom. 
Zaklju~ak: Netradicionalni pokazatelji gojaznosti, BAI i CMI
su nezavisno povezani sa ve}im vrednostima  endo kana u
populaciji odraslih.
Klju~ne re~i: kardiometaboli~ki rizik, endokan, infla -
macija, gojaznost
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The BAI was calculated by the following equa-
tion (20):
HC (cm) ÷ height (m)1.5 – 18,
The BRI was calculated, as follows (21):
BRI = 364.2−365.5 x √ 1−(WC/2p)2 / (0.5 x
height)2,
The CI was calculated using the equation (22):
CI = WC (cm) / 0.109 x weight (kg)/height
(cm)
ABSI was calculated, as follows (23):
WC/(BMI2/3 x height1/2), expressed in m11/6
kg−2/3.
The CMI was calculated using the formula (24): 
CMI = TG/HDL-c × WHtR,
where triglycerides (TG) and high density
lipoprotein cholesterol (HDL-c) are expressed in
mmol/L.
The VAI was calculated, as follows (25):
WC/36.58 + (1.89 × BMI) × (TG/0.81) ×
(1.52/HDL-c)} for women, and WC/39.68 + (1.88
× BMI) × (TG/1.03) × (1.31/HDL-c) for men,
where WC is expressed in cm, BMI in kg/m2, TG
and HDL-c in mmol/L.
The LAP was calculated using the formula (26): 
LAP = (WC - 58) x TG for females, and (WC-
65) x TG for males,
where WC is expressed in cm, and TG in
mmol/L.
Methods
The blood samples were taken in 7.00–9.00
a.m. after participants fasted at least 8 hours. In order
to obtain sera, samples were left to clot within 30
minutes and then centrifuged at room temperature
for 10 minutes at 3000xg. 
Serum endocan levels were determined by using
an enzyme-linked immunosorbent commercial assay
(ab213776 – Human ESM1 ELISA Kit, Abcam,
Cambridge, UK). 
Immunoturbidimetric method was used for
determination of HbA1c in samples of a whole blood
Roche Cobas c501 chemistry analyzer (Roche
Diagnostics GmbH, Mannheim, Germany). Serum
glucose and lipid parameters (i.e., TG and HDL-c)
were measured spectrophotometrically, on the same
autoanalyzer as HbA1c. Serum hsCRP level was
obtained by nephelometric assay (Behring Nephelo -
meter Analyzer, Marburg, Germany).
Statistical analysis
Data distribution was examined by Kolmogorov-
Smirnov test. Normally distributed data were present-
ed as arithmetic mean±standard deviation and com-
pared by one-way analysis of variance with Tuckey
post hoc test. Data with distribution that achieved nor-
mality after logarithmic transformation were present-
ed as geometric mean and 95% Confidence Interval
and compared by one-way analysis of variance with
Tuckey post hoc test. Skewed distributed data were
presented as median (interquartile range) and com-
pared by Kruskal-Wallis and Mann-Whitney tests,
depended on the number of tested groups.
Categorical variables were compared by Chi-square
test for contingency and presented as absolute fre-
quencies.
Associations of endocan and anthropometric
data were tested by non-parametric Spearman’s cor-
relation analysis and data were presented as Spear -
man’s coefficient correlation (r). Ordinal regression
analysis was used to estimate potential independent
prediction of anthropometric markers (independent
variables) on endocan levels (dependent variable
given as tertiles). All the assumptions for univariate
and multivariate ordinal regression analysis were
taken into account when performing such statistical
analysis. Those were as follows: model fitting infor-
mation had significant Chi-square value (P<0.05),
goodness-of-fit test had P>0.05 and test of parallel
lines had P>0.05. Also, anthropometric markers
were tested for multicollinearity and those which were
in mutual collinearity (VIF>4) were excluded from the
models. Inclusion criteria for markers entering the mod-
els were those that had significant correlation with en -
docan levels when tested by Spearman’s correlation
analysis for continuous variables and statistical signif-
icant difference between endocan tertile groups test-
ed by Chi-square test for categorical data. Data from
these analyses were presented as the estimated odds
ratio (95% Confidence Intervals). The explained variation
in endocan levels was given by Nagelkerke R2 value.
Statistical analyses were performed using SPSS®
Statistic version 22 (Chicago, USA). Two-tailed P val-
ues less than 0.05 were set as statistically significant.
Results
Anthropometric characteristics of study population
according to endocan tertiles levels were shown in
Table I. Tested groups had similar gender, hypo -
lipidemic and antihypertensive users distribution. Also,
examinees were of similar age in all three groups. The
lowest number of smokers was in the third endocan
tertile group. The patients in the highest endocan
tertile group had higher weight, BMI, WC, HC, WHtR,
BAI, BRI and LAP than those from the first and the
second tertile group.
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Non-parametric Spearman’s correlation analysis
revealed that endocan correlated positively with age,
weight, BMI, WC, HC, WHtR, BAI, BRI, CMI, VAI and
LAP (Table II). However, the mentioned correlations
are relatively weak.
Anthropometric data that showed significant
Spearman’s correlation coefficient were further tested
by regression analysis. Results of univariate and mul-
tivariate ordinal regression analysis of endocan tertile
levels as dependent variable and anthropometric data
as independent variables were given in Table III. 
Univariate regression analysis demonstrated sig-
nificant positive correlations of endocan and almost
all anthropometric data. Positive association of endo-
can and VAI had borderline statistical significance. To
explore the independent associations of endocan and
anthropometric data, the Model which fulfilled criteria
for ordinal regression testing was created. Adjusted
odds for BAI given in the Model (OR=1.120, 95% CI
1.036–1.212, P=0.004), demonstrated that a rise in
BAI by 1 unit increased the probability of higher
endocan concentration by 12%. As well, adjusted
odds for CMI reached statistical significance, demon-
strating that a rise in CMI for 1 unit, raised probability
for higher endocan levels for 2.6 times (OR=2.599,
95% CI 1.006–6.712, P=0.049). Nagelkerke R2 for
the Model was 0.201 which indicated that 20.1% of
variation in endocan levels could be explained by the
Model. 
Data are presented as arithmetic mean ± standard deviation and compared by one-way ANOVA with Tuckey post hoc test. 
†Data are presented as median (interquartile range) and compared by Kruskal-Wallis and Mann-Whitney tests.
†† Data are presented as geometric mean (95% Confidence Interval) and compared by one-way ANOVA with Tuckey post hoc test
after logarithmic transformation. 
a-significantly different from the first endocan tertile group
b-significantly different from the second endocan tertile group
*P<0.001; # P<0.01, ‡ P<0.05
BMI-Body mass index; WC-Waist circumference; HC-Hip circumference; WHtR-Waist-to-Height ratio; WHR-Waist-to-Hip ratio; BAI-
Body adiposity index; CI-Conicity index; BRI-Body roundness index; ABSI-A body shape index; CMI-Cardiometabolic index; VAI-
Visceral adiposity index; LAP-Lipid accumulation product index 
Table I Anthropometric data according to endocan tertiles.
The first endocan 
tertile group
The second endocan 
tertile group
The third endocan 
tertile group P
N (male/female) 59 (21/38) 59 (15/44) 59 (16/43) 0.430
Age, years 58.9±10.4 60.9±9.2 61.8±9.5 0.270
Smokers, (yes/no) 18/41 15/44 5/54 0.009
Hypolipidemics, (yes/no) 15/44 19/40 12/47 0.337
Antihypertensives, (yes/no) 25/34 33/26 35/24 0.149
Weight, kg† 77 (70–88) 76 (66–88) 81 (76–94)a‡,b# 0.007
Height, cm† 170 (164–175) 168 (162–172) 165 (162–174) 0.282
BMI, kg/m2† 26.8 (25.2–28.6) 26.8 (24.0–29.0) 30.5 (27.9–32.6)a*,b* <0.001
WC, cm 95±9 94±11 100±9a‡,b# 0.001
HC, cm 105±7 105±9 111±7a*,b* <0.001
WHtR† 0.55 (0.53–0.58) 0.55 (0.51–0.60) 0.59 (0.56–0.63)a*,b* <0.001
WHR 0.90±0.07 0.89±0.07 0.90±0.06 0.384
BAI 29.51±4.63 30.53±4.68 33.66±4.59a*,b# <0.001
CI 1.28±0.07 1.27±0.08 1.29±0.06 0.426
BRI†† 4.42 (4.18–4.68) 4.37 (4.06–4.71) 5.31 (5.04–5.60)a*,b* <0.001
ABSI 0.08±0.01 0.08±0.01 0.08±0.01 0.827
CMI† 0.46 (0.35–0.99) 0.75 (0.37–1.11) 0.96 (0.50–1.26) 0.058
VAI†† 15.1 (12.1–18.8) 1.73 (1.46–2.06) 1.91 (1.60–2.27) 0.128
LAP† 45.98 (31.51–73.01) 59.40(35.25–84.09) 78.00 a*,b*(49.66–99.90) 0.006
Endocan, ng/L 1.51 (1.21–1.88) 30.3 (24.5–34.9)a* 84.9 (59.3–105.4)a*,b* <0.001
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Discussion
As far as we are aware, this is the first study that
evaluated potential relationship between endocan
and non-traditional anthropometric indices.
The results of the current research show that not
only that serum endocan levels positively correlated
with the majority of examined anthropometric
parameters in univariate regression analysis, but novel
obesity indexes, such as BAI and CMI correlated with
this biomarker independently in adult population.
Similarly, the utility of BAI and CMI for
estimating the cardiometabolic risk factors, such as
the risk of hypertension and hyperuricemia (19, 27)
was also shown in previous studies.
Our findings are opposite to previous reports of
the inverse association between endocan level and
traditional obesity indexes, BMI and/or WC (12–15).
The possible discrepancies in such results may be
explained with the age and sex differences, as well as
different ethnic groups that previous studies included.
Also, the extent of obesity and phenotypes of
adiposity vary significantly among individuals which
may also explain this controversies.
The BMI is the most common used parameter
for the general obesity assessment. However, it has
some drawbacks, which can not give information on
the body shape and distribution of adipose tissue,
neither can distiguish fat depots and muscle mass
(19). 
The WC, WHR, and WHtR can provide better
information on abdominal obesity than BMI. But the
latter ones are limitted to fully differentiate visceral
from subcutaneous fat (19).
In order to overcome these drawbacks of
traditional anthropometric parameters, some novel
obesity indices are emerged (27).
The BAI is derived from HC and height
measurements and estimates subcutaneous adipose
tissue and the body fat percentage better than BMI
(20), and represents better screening tool for
coronary risk in adult population than BMI (28). The
three other indices that assess body shape, BRI (i.e.
derived from height and WC), CI and ABSI (i.e. both
calculated from weight, height and WC) are also
shown to be convenient predictors of body fat
distribution (21–23).
The new indicators of abdominal obesity (i.e.
CMI, VAI, and LAP), beside WC include lipid
parameters to better differentiate subcutaneous from
visceral adipose tissue, and to better discriminate
cardiometabolic risk than traditional indices (24–26).
Additionally, CMI besides WHtR, include TG/HDL-c
ratio (24) which inversely correlates with the plasma
level of small dense LDL particles, that are more
atherogenic than larger LDL-particles (29).
Table II Spearman’s correlation analysis of endocan and
anthropometric characteristics.
Table III Estimated odds ratios after ordinal regression
analysis for endocan tertile levels.
Data are presented as correlation coefficient Rho (r).
BMI-Body mass index; WC-Waist circumference; HC-Hip
circumference; WHtR-Waist-to-Height ratio; WHR-Waist-to-Hip
ratio; BAI-Body adiposity index; CI-Conicity index; BRI-Body
roundness index; ABSI-A body shape index; CMI-
Cardiometabolic index; VAI-Visceral adiposity index; LAP-Lipid
accumulation product index 
Rho (r) P
Age, years 0.180 0.017
Weight, kg 0.154 0.040
Height, cm -0.110 0.145
BMI, kg/m2 0.284 <0.001
WC, cm 0.215 0.004











OR (95% CI) P R2
Age, years 1.024 (0.995–1.053) 0.101 0.017
Weight, kg 1.019 (1.001–1.039) 0.043 0.027
BMI, kg/m2 1.141 (1.062–1.225) <0.001 0.090
WC, cm 1.038 (1.010–1.066) 0.008 0.048
HC, cm 1.082 (1.043–1.124) <0.001 0.118
BAI 1.151 (1.082–1.225) <0.001 0.133
BRI 1.559 (1.230–1.978) <0.001 0.090
CMI 1.835 (1.106–3.043) 0.019 0.040
VAI 1.215 (1.000–1.475) 0.050 0.026
LAP 1.012 (1.003–1.020) 0.005 0.050
Adjusted – Model
OR (95% CI) P R2
BAI 1.120 (1.036–1.212) 0.004
0.201
BRI 1.183 (0.745–1.876) 0.477
CMI 2.599 (1.006–6.712) 0.049
LAP 0.990 (0.973–1.008) 0.269
Model included age, BMI, BAI, BRI, CMI, LAP (all continuous
variables) and smoking status (categorical variable).
BMI – Body mass index; WC – Waist circumference; HC – Hip
circumference; BAI – Body adiposity index; BRI – Body
roundness index; CMI – Cardiometabolic index; VAI – Visceral
adiposity index; LAP – Lipid accumulation product index 
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In our study, among all examined traditional and
novel anthropometric indexes, BAI and CMI corre -
lated independently with endocan in adult popu -
lation. These findings might enable easier assessment
of phenotypes of adiposity that are related to higher
endocan level, and consequently higher cardio -
metabolic risk. These indexes are cost-effective and
easy-obtained in everyday clinical practice.
The first study that examined endocan in
relation to adipose tissue was conducted by Wellner et
al. (30) showing that adipocytes express endocan
(previously known as endothelial specific molecule,
ESM-1). In line with this Janke and al. (11) reported
lower serum endocan levels in overweight/obese
postmenopausal women. They also provided sub -
cutaneous abdominal adipose tissue from those
women and showed higher expression of endocan in
human adipocytes than in preadipocytes. Intere -
stingly, after weight loss programme, serum endocan
levels significantly increased, but its expression in
adipocytes did not change, suggesting that some
other sites of endocan secretion may be more
important (e.g. lungs, kidneys) (11).
Our study included more participants that
Janke’s et al. (11) did and examined both genders.
This might explain discordant results. Additionally, we
excluded each participant with acute inflammation, to
diminish confounding efects on serum endocan level.
Namely, it was shown that many pro-inflammatory
cytokines induce endocan expression in vitro (e.g.,
interleukin-1, vascular endothelial growth factor,
tumor necrosis factor-alpha, transforming growth
factor-beta-1, fibroblast growth factor-2) (31), and
some mytogens in adipocytes (e.g., retinoic acid and
phorbol ester) (30).
Recently, endocan expression was also reported
to be increased in the human placenta from obese
women with gestational diabetes mellitus (32) and in
reaction to pro-inflammatory stimuli, thus implying
that endocan may take part in the states caracterized
with increased inflammation. Indeed, not only that
the expression of this biomarker is increased by
different cytokines’ stimuli, but endocan per se can
trigger endothelial cells to secrete a wide spectrum of
other cytokines and enhance leukocytes migration.
Moreover, its influence on increased blood vessels
permeability is detected, which altogether makes this
biomarker reliable for increased cardiometabolic risk
recognition (33).
The limitation of this study is its cross-sectional
design which can not confirm the causal relationship
between endocan and obesity indexes. Furthermore,
in the second and the third endocan tertile group
there were more females than males than in the first
group, and the gender effect might be some source
of bias. As well, patients were not asked to
discontinue antihypertensive and lipid lowering
therapy, which might affect serum endocan levels, as
well as some anthropometric indices (CMI, VAI, LAP).
At last, we were not able to use precise imaging
techniques, for more accurate assessment of visceral
compartments. However, contrary to some previous
studies, we have shown the positive association of
endocan with a wide spectrum of anthropometric
indices, both traditional and non-traditional ones.
Future studies which will include participants with
obesity, without other comorbidities and without any
medicament therapy use, might be useful to better
evaluate the influence of obesity on serum endocan
level. 
Conclusion
Non-traditional obesity indices, BAI and CMI
independently correlated with higher serum endocan
levels in adult population. Screening for obesity with
paying attention on both, total body fat (determined
by increased BAI) and visceral adipose tissue
distribution (defined by higher CMI) might be useful
to differentiate patients with higher endocan levels,
and consequently higher cardiometabolic risk. New
prospective studies are needed to confirm our results
and enlighten the causal relationship between
endocan and obesity indexes.
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